Back to News
Market Impact: 0.2
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP reminded investors of a shareholder class-action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The release provides no details on alleged damages, litigation timeline, or operational impact, but the lawsuit presents a reputational and legal overhang for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
CAPR-0.85
More News
- Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026
- SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026
- Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026
- Bloomberg Law: No Breakup of Google & Clippers Fined (Podcast)
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026